Status:
UNKNOWN
Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Lead Sponsor:
Cairo University
Conditions:
Lichen Planus
Eligibility:
All Genders
18+ years
Brief Summary
Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Detailed Description
This prospective Case Control study will be conducted at Kasr Al-Aini Dermatology Outpatient Clinics and will include 30 LP patients and 30 normal healthy controls which will be recruited and assessed...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age group above 18 years old
- Patients of both genders
- Classic type of cutaneous LP.
- Exclusion criteria:
- Topical treatment for LP 2 weeks before enrollment in the study or systemic treatment for LP 4 weeks before enrollment in the study and 3 years for systemic retenoids.
- Actinic LP , LP pigmentosus and Mucosal only LP
- Drug induced lichenoid eruption
- Conditions precluding taking skin biopsy : bleeding tendency , lidocaine allergy
- PD-1 associated-diseases e.g.: SLE, Cancers including melanoma and non-melanoma skin cancers, and Bullous Pemphigoid
Exclusion
Key Trial Info
Start Date :
June 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 22 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04892381
Start Date
June 18 2021
End Date
April 22 2022
Last Update
May 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt